Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study

被引：10

作者：

Tershakovec, Andrew M. ^{[1
]}

Keane, William F. ^{[1
]}

Zhang, Zhongxin ^{[1
]}

Lyle, Paulette A. ^{[1
]}

Appel, Gerald B. ^{[2
]}

McGill, Janet B. ^{[3
]}

Parving, Hans-Henrik ^{[4
]}

Cooper, Mark E. ^{[5
]}

Shahinfar, Shahnaz ^{[1
]}

Brenner, Barry M. ^{[6
]}

机构：

[1] Merck & Co Inc, Merck Res Labs, N Wales, PA 19454 USA

[2] Columbia Univ, Dept Clin Nephrol, New York, NY USA

[3] Washington Univ, Div Endocrinol Metab & Lipid Res, St Louis, MO USA

[4] Univ Copenhagen Hosp, Dept Med Endocrinol, DK-2100 Copenhagen, Denmark

[5] Baker Heart Res Inst, Melbourne, Vic, Australia

[6] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA

来源：

DIABETES CARE | 2008年 / 31卷 / 03期

关键词：

D O I：

10.2337/dc07-0196

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Renal pathology and dyslipidemia commonly coexist. Treatments that lower albuminuria/ proteinuria may lower lipids, but it is not known whether lipid lowering independent of lessening albuminuria/proteinuria slows progression of kidney disease. We examined the association between LDL cholesterol levels and treatment with losartan on end-stage renal disease (ESRD). Lipid levels and albuminuria measurements were obtained at baseline and at year I in a post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, which compared the effects of losartan-versus placebo-based antihypertensive therapy in patients with type 2 diabetes and nephropathy. LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria.

引用

页码：445 / 447

页数：3

共 50 条

[1] Losartan reduces the costs associated with diabetic end-stage renal disease - The RENAAL study economic evaluation
Herman, WH
Shahinfar, S
Carides, GW
Dasbach, F
Gerth, WC
Alexander, CM
Cook, JR
Keane, WF
Brenner, BM
DIABETES CARE, 2003, 26 (03) : 683 - 687
[2] Losartan reduces the costs associated with diabetic end-stage renal disease: The RENAAL study economic evaluation
Herman, WH
Shahinfar, S
Carides, GW
Dasbach, EJ
Gerth, WC
Alexander, CM
Cook, JR
Keane, WF
Brenner, BM
DIABETES, 2002, 51 : A28 - A28
[3] Losartan and anaemia of end-stage renal disease
Lang, SM
Schiffl, H
LANCET, 1998, 352 (9141): : 1708 - 1708
[4] The impact of losartan on the lifetime incidence of end-stage renal disease and associated costs: Lifetime projections based on the RENAAL study.
Keane, WF
Carides, GW
Shahinfar, S
Dasbach, EJ
Gerth, WC
Alexander, CM
Herman, WH
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 264A - 265A
[5] Losartan reduces the medical burden and costs associated with End-Stage Renal Disease (ESRD). Implications from the RENAAL Study for Germany.
Liebl, A
Carides, GW
Gerth, WC
Krobot, KJ
DIABETOLOGIA, 2002, 45 : A301 - A302
[6] Losartan potassium: no aggravation of anaemia of end-stage renal disease
Reactions Weekly, 1998, 729 (1) : 5 - 5
[7] The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study
Keane, WF
Brenner, BM
de Zeeuw, D
Grunfeld, JP
McGill, J
Mitch, WE
Ribeiro, AB
Shahinfar, S
Simpson, RL
Snapinn, SM
Toto, R
KIDNEY INTERNATIONAL, 2003, 63 (04) : 1499 - 1507
[8] LDL particle size and number compared with LDL cholesterol and risk categorization in end-stage renal disease patients
Bowden, Rodney G.
Wilson, Ronald L.
Beaujean, A. Alexander
JOURNAL OF NEPHROLOGY, 2011, 24 (06) : 771 - 777
[9] Pharmacokinetics and blood pressure response of losartan in end-stage renal disease
Sica, DA
Halstenson, CE
Gehr, TWB
Keane, WF
CLINICAL PHARMACOKINETICS, 2000, 38 (06) : 519 - 526
[10] Pharmacokinetics and Blood Pressure Response of Losartan in End-Stage Renal Disease
Domenic A. Sica
Charles E. Halstenson
Todd W. B. Gehr
William F. Keane
Clinical Pharmacokinetics, 2000, 38 : 519 - 526

← 1 2 3 4 5 →